Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

54.47 5.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

51.77

Max

54.52

Galvenie mērījumi
By Trading Economics
Ienākumi	136M -93M
Pārdošana	43M 246M
EPS	-0.3
Peļņas marža	-37.599
Darbinieki	1,402
EBITDA	-4.7B -69M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+74.1% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 28. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-2.7B 9.2B
Iepriekšējā atvēršanas cena	49.25
Iepriekšējā slēgšanas cena	54.47

Ziņu noskaņojums

By Acuity

100%

320 / 340 Rangs Healthcare

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. aug. 00:06 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, recovering from recent declines amid broader market gains, including a rise in the Nikkei 225 Index.

2026. g. 31. jūl. 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market hours, supported by a notable advance in the Biotechnology sub-sector. No specific news was identified.

2026. g. 30. jūl. 23:46 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours, though no specific news explains the movement amid mixed Asian equity performance and geopolitical concerns.

2026. g. 29. jūl. 23:51 UTC

Ionis Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of four consecutive sessions below its 20-day moving average.

2026. g. 28. jūl. 18:03 UTC

News

Ionis Pharmaceuticals shares are lower amid an investigation by Bronstein, Gewirtz & Grossman and disappointing earnings forecasts projecting a loss of $1.07 per share.

2026. g. 27. jūl. 20:07 UTC

News

Social Media

Ionis Pharmaceuticals shares are lower amid an investigation into potential claims following the company's disclosure about its failed Phase-3 trial.

2026. g. 25. jūl. 00:02 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, diverging from recent gains. No specific news was identified to explain the decline.

2026. g. 24. jūl. 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, following a broader market decline driven by disappointing earnings from major companies and falling crude oil prices.

2026. g. 23. jūl. 20:03 UTC

Ionis Pharmaceuticals Inc shares are higher during Thursday's session, continuing a notable increase since Wednesday. Trading volume is unusually high today.

2026. g. 22. jūl. 22:26 UTC

Ionis Pharmaceuticals shares are slightly higher in after-market hours. Broader market conditions reflect ongoing geopolitical tensions and rising crude oil prices.

2026. g. 21. jūl. 21:01 UTC

Ionis Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline. The broader market is rebounding.

2026. g. 20. jūl. 23:01 UTC

Ionis Pharmaceuticals Inc shares are higher in after-market trading, recovering from earlier lows after three consecutive daily declines. No specific news was identified.

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

74.1% augšup

Prognoze 12 mēnešiem

Vidējais 90.13 USD 74.1%

Augstākais 115 USD

Zemākais 68 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.